Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the effectiveness and safety of atomoxetine in enhancing attention and concentration among childhood survivors of cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Temple University
• Collaborator: Eli Lilly and Company
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• Age 6-18

• Patient has received chemotherapy, radiation, or a combination of both.

• Patient is at least 12 months post-competion of therapy but no more than five years post-completion of therapy.

Exclusion Criteria:

• No ongoing pharmacological management of ADHD

• Not currently pregnant